Version Française
OK
Logo retour accueil

Last news

  • Collaboration with PICCOLO study investigators

    IntegraGen has announced a collaboration with the team of investigators from the PICCOLO study to further validate the role of biomarker hsa-miR-31-3p in metastatic colorectal cancer (mCRC).

    Read more

  • IntegraGen licences liver cancer molecular signatures

    IntegraGen has announced that it has entered into an agreement providing the company with the worldwide licensing rights for two hepatocellular carcinoma molecular signatures which have potential clinical utility for monitoring patients with liver cancer.

    Read more

Home

IntegraGen's mission is to translate molecular research to clinical practice through the identification of novel genetic biomarkers and the subsequent commercialization of molecular diagnostic tests for autism and oncology based on these discoveries. The company also strives to be a leader in providing cutting edge genomic services to academic researchers and life sciences companies based on it's technological expertise and scientific know how.



Autism Oncology Services
Disclaimers - Mentions légales - Crédits